Achieve Life Sciences’ (ACHV) Buy Rating Reiterated at HC Wainwright

Posted by Francis Steltz on Jun 22nd, 2026

Achieve Life Sciences (NASDAQ:ACHV – Get Free Report)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research note issued on Monday,Benzinga reports. They presently have a $12.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s target price suggests a potential upside of 125.14% from the stock’s current price.

Several other equities analysts also recently commented on the stock. Weiss Ratings upgraded shares of Achieve Life Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. Wall Street Zen upgraded Achieve Life Sciences from a “sell” rating to a “hold” rating in a research note on Sunday, May 17th. Finally, Canaccord Genuity Group set a $13.00 target price on Achieve Life Sciences and gave the stock a “buy” rating in a research report on Monday, April 20th. Two equities research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $14.67.

Get Our Latest Report on ACHV

Achieve Life Sciences Price Performance

Achieve Life Sciences stock traded up $0.48 during mid-day trading on Monday, hitting $5.33. The stock had a trading volume of 1,209,801 shares, compared to its average volume of 1,122,220. The firm has a market capitalization of $547.18 million, a P/E ratio of -4.79 and a beta of 2.27. The company has a current ratio of 2.62, a quick ratio of 2.62 and a debt-to-equity ratio of 0.87. The firm’s 50 day moving average is $4.81 and its 200 day moving average is $4.55. Achieve Life Sciences has a one year low of $2.00 and a one year high of $6.16.

Achieve Life Sciences (NASDAQ:ACHV – Get Free Report) last issued its earnings results on Tuesday, May 12th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.11. On average, sell-side analysts forecast that Achieve Life Sciences will post -0.91 earnings per share for the current fiscal year.

Institutional Trading of Achieve Life Sciences

Institutional investors have recently made changes to their positions in the business. AQR Capital Management LLC purchased a new stake in Achieve Life Sciences during the 1st quarter valued at about $32,000. Sender Co & Partners Inc. purchased a new stake in Achieve Life Sciences in the second quarter valued at approximately $56,000. OneDigital Investment Advisors LLC purchased a new stake in Achieve Life Sciences in the third quarter valued at approximately $63,000. Magnolia Capital Advisors LLC purchased a new stake in Achieve Life Sciences in the fourth quarter valued at approximately $64,000. Finally, Bank of America Corp DE increased its holdings in Achieve Life Sciences by 39.9% in the 2nd quarter. Bank of America Corp DE now owns 33,731 shares of the biopharmaceutical company’s stock worth $76,000 after buying an additional 9,617 shares during the period. Institutional investors and hedge funds own 33.52% of the company’s stock.

Achieve Life Sciences Company Profile

(Get Free Report)

Achieve Life Sciences, Inc (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.